Analystreport

Coherus Biosciences Inc (NASDAQ: CHRS) had its "buy" rating re-affirmed by analysts at Maxim Group. They now have a $27.00 price target on the stock.

Coherus BioSciences, Inc.  (CHRS) 
Last coherus biosciences, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: investors.coherus.com